They found that tumors with a high ICI score had a better prognosis, which was characterized by increased tumor mutational burden (TMB), increased expression of genes involved in immune checkpoints, chemokines, and the interleukin-17 (IL-17) signaling pathway. The gene discussed is IL17A; the disease is neoplasm.